Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis
8.9% sustained all grade cardiotoxicity, while 4.4% sustained high-grade cardiotoxicity with carfilzomib. All-grade hypertension was present in 13.2% of patients. No difference in the event rate between newly diagnosed multiple myeloma patients and those with relapsed/refractory cancer.
